{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:43:42Z","timestamp":1793040222086,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud y Familias, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["RIC-0111-2019"],"award-info":[{"award-number":["RIC-0111-2019"]}],"id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009473","name":"Universidad de M\u00e1laga","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009473","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s40263-024-01063-6","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T14:36:44Z","timestamp":1706107004000},"page":"141-151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3414-2707","authenticated-orcid":false,"given":"Pedro J","family":"Serrano-Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5207-1159","authenticated-orcid":false,"given":"Teresa","family":"Ram\u00edrez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-5348","authenticated-orcid":false,"given":"Pablo","family":"Cabezudo-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3894-9716","authenticated-orcid":false,"given":"Guillermina","family":"Garcia-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4443-8931","authenticated-orcid":false,"given":"Juan","family":"De La Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"1063_CR1","unstructured":"Sociedad Espa\u00f1ola de Neurolog\u00eda. Manual de Pr\u00e1ctica Cl\u00ednica en Epilepsia. Recomendaciones diagnostico-terap\u00e9uticas de la SEN [Internet]. 2019 [cited 2021 Nov 11]. http:\/\/epilepsia.sen.es\/wp-content\/uploads\/2020\/06\/Recomendaciones-Epilepsia-SEN-2019.pdf"},{"issue":"3","key":"1063_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","volume":"75","author":"Z Chen","year":"2018","unstructured":"Chen Z, Brodie MJ, Liew D, et al. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279\u201386.","journal-title":"JAMA Neurol"},{"key":"1063_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.seizure.2016.11.022","volume":"44","author":"A Golyala","year":"2017","unstructured":"Golyala A, Kwan P. Drug development for refractory epilepsy: the past 25\u00a0years and beyond. Seizure. 2017;44:147\u201356.","journal-title":"Seizure"},{"key":"1063_CR4","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1212\/WNL.0000000000011839","volume":"96","author":"B Sultana","year":"2021","unstructured":"Sultana B, Panzini MA, Veilleux Carpentier A, et al. Incidence and prevalence of drug-resistant epilepsy: a systematic review and meta-analysis. Neurology. 2021;96:805\u201317.","journal-title":"Neurology"},{"key":"1063_CR5","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1212\/WNL.58.8_suppl_5.S9","volume":"58","author":"F Gilliam","year":"2002","unstructured":"Gilliam F. Optimizing health outcomes in active epilepsy. Neurology. 2002;58:S9-20.","journal-title":"Neurology"},{"key":"1063_CR6","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s00415-018-8971-z","volume":"265","author":"RA Sarkis","year":"2018","unstructured":"Sarkis RA, Goksen Y, Mu Y, et al. Cognitive and fatigue side effects of anti-epileptic drugs: an analysis of phase III add-on trials. J Neurol. 2018;265:2137\u201342.","journal-title":"J Neurol"},{"key":"1063_CR7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.seizure.2012.06.013","volume":"21","author":"T Andrew","year":"2012","unstructured":"Andrew T, Milinis K, Baker G, et al. Self-reported adverse effects of mono and polytherapy for epilepsy. Seizure. 2012;21:610\u20133.","journal-title":"Seizure"},{"key":"1063_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.seizure.2015.03.013","volume":"29","author":"A Javed","year":"2015","unstructured":"Javed A, Cohen B, Detyniecki K, et al. Rates and predictors of patient-reported cognitive side effects of antiepileptic drugs: an extended follow-up. Seizure. 2015;29:34\u201340.","journal-title":"Seizure"},{"key":"1063_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.yebeh.2005.01.002","volume":"6","author":"N Fritz","year":"2005","unstructured":"Fritz N, Glogau S, Hoffmann J, et al. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav. 2005;6:373\u201381.","journal-title":"Epilepsy Behav"},{"key":"1063_CR10","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s40263-022-00955-9","volume":"36","author":"A Strzelczyk","year":"2022","unstructured":"Strzelczyk A, Schubert-Bast S. Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies. CNS Drugs. 2022;36:1079\u2013111.","journal-title":"CNS Drugs"},{"key":"1063_CR11","unstructured":"ONTOZRY Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ontozry-epar-product-information_en.pdf. Accessed Aug 2023."},{"key":"1063_CR12","unstructured":"XCOPRI Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212839s000lbl.pdf. Accessed Aug 2023."},{"issue":"22","key":"1063_CR13","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","volume":"94","author":"SS Chung","year":"2020","unstructured":"Chung SS, French JA, Kowalski J, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311\u201322.","journal-title":"Neurology"},{"issue":"1","key":"1063_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38\u201348.","journal-title":"Lancet Neurol"},{"key":"1063_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.seizure.2022.10.004","volume":"102","author":"E Schuetz","year":"2022","unstructured":"Schuetz E, Wagner K, Metternich B, et al. Effects of cenobamate on cognitive performance of epilepsy patients. Seizure. 2022;102:129\u201333.","journal-title":"Seizure"},{"issue":"5","key":"1063_CR16","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/epi.12962","volume":"56","author":"SJ Wilson","year":"2015","unstructured":"Wilson SJ, Baxendale S, Barr W, et al. Indications and expectations for neuropsychological assessment in routine epilepsy care: report of the ILAE Neuropsychology Task Force, Diagnostic Methods Commission, 2013\u20132017. Epilepsia. 2015;56(5):674\u201381.","journal-title":"Epilepsia"},{"key":"1063_CR17","doi-asserted-by":"crossref","unstructured":"Pe\u00f1a-Casanova J, Gramunt-Fombuena N, Qui\u00f1ones-Ubeda S, et al., NEURONORMA Study Team. Spanish Multicenter Normative Studies (NEURONORMA Project): norms for the Rey\u2013Osterrieth complex figure (copy and memory), and free and cued selective reminding test. Arch Clin Neuropsychol. 2009;24(4):371\u201393.","DOI":"10.1093\/arclin\/acp041"},{"issue":"5","key":"1063_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.nrl.2018.02.002","volume":"36","author":"L Grau-Guinea","year":"2021","unstructured":"Grau-Guinea L, P\u00e9rez Enr\u00edquez C, Garc\u00eda-Escobar G, et al. Development, equivalence study, and normative data of version B of the Spanish-language Free and Cued Selective Reminding Test. Neurologia. 2021;36(5):353\u201360.","journal-title":"Neurologia"},{"key":"1063_CR19","volume-title":"Test de copia y de reproducci\u00f3n de memoria de figuras geom\u00e9tricas complejas","author":"A Rey","year":"2003","unstructured":"Rey A. Test de copia y de reproducci\u00f3n de memoria de figuras geom\u00e9tricas complejas. Madrid: TEA Ediciones, S.A; 2003."},{"key":"1063_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nrl.2017.07.001","volume":"35","author":"AG Jaimes-Bautista","year":"2020","unstructured":"Jaimes-Bautista AG, Rodr\u00edguez-Camacho M, Mart\u00ednez-Ju\u00e1rez IE, et al. An\u00e1lisis cuantitativo y cualitativo de la fluidez verbal sem\u00e1ntica en pacientes con epilepsia del l\u00f3bulo temporal. Neurologia. 2020;35:1\u20139.","journal-title":"Neurologia"},{"key":"1063_CR21","doi-asserted-by":"crossref","unstructured":"Pe\u00f1a-Casanova J, Qui\u00f1ones-Ubeda S, Gramunt-Fombuena N, et al., NEURONORMA Study Team. Spanish Multicenter Normative Studies (NEURONORMA Project): norms for verbal fluency tests. Arch Clin Neuropsychol. 2009;24(4):395\u2013411.","DOI":"10.1093\/arclin\/acp042"},{"key":"1063_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1017\/S1355617709990415","volume":"15","author":"T Torralva","year":"2009","unstructured":"Torralva T, Roca M, Gleichgerrcht E, et al. INECO Frontal Screening (IFS): a brief, sensitive, and specific tool to assess executive functions in dementia. J Int Neuropsychol Soc. 2009;15:777\u201386.","journal-title":"J Int Neuropsychol Soc"},{"key":"1063_CR23","unstructured":"Wechsler D. Escala de Inteligencia de Wechsler para adultos-III. Manuel de aplicaci\u00f3n y correcci\u00f3n. 3\u00b0 Edici\u00f3n. Madrid: TEA Ediciones, S.A; 2001."},{"key":"1063_CR24","doi-asserted-by":"crossref","unstructured":"Pe\u00f1a-Casanova J, Qui\u00f1ones-Ubeda S, Quintana-Aparicio M, et al., NEURONORMA Study Team. Spanish Multicenter Normative Studies (NEURONORMA Project): norms for verbal span, visuospatial span, letter and number sequencing, trail making test, and symbol digit modalities test. Arch Clin Neuropsychol. 2009;24(4):321\u201341.","DOI":"10.1093\/arclin\/acp038"},{"key":"1063_CR25","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1038\/nprot.2006.390","volume":"1","author":"CR Bowie","year":"2006","unstructured":"Bowie CR, Harvey PD. Administration and interpretation of the Trail Making Test. Nat Protoc. 2006;1:2277.","journal-title":"Nat Protoc"},{"key":"1063_CR26","first-page":"824","volume":"38","author":"MA Sed\u00f3","year":"2004","unstructured":"Sed\u00f3 MA. \u20185 digit test\u2019: a multilinguistic non-reading alternative to the Stroop test. Rev Neurol. 2004;38:824\u20138.","journal-title":"Rev Neurol"},{"key":"1063_CR27","unstructured":"Sed\u00f3 MA. Manual del Test de los 5 d\u00edgitos. TEA Ediciones. 2009. https:\/\/web.teaediciones.com\/FDT--TEST-DE-LOS-CINCO-DIGITOS.aspx. Accessed 18 Jan 2024."},{"key":"1063_CR28","first-page":"1026","volume":"31","author":"BL Brooks","year":"2016","unstructured":"Brooks BL, Holdnack JA, Iverson GL. To change is human: \u201cabnormal\u201d reliable change memory scores are common in healthy adults and older adults. Arch Clin Neuropsychol. 2016;31:1026\u201336.","journal-title":"Arch Clin Neuropsychol"},{"issue":"10","key":"1063_CR29","doi-asserted-by":"publisher","first-page":"e989","DOI":"10.1212\/WNL.0000000000200792","volume":"99","author":"P Klein","year":"2022","unstructured":"Klein P, Aboumatar S, Brandt C, et al. Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2022;99(10):e989\u201398.","journal-title":"Neurology"},{"key":"1063_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.950171","volume":"13","author":"KL Makridis","year":"2022","unstructured":"Makridis KL, Bast T, Prager C, et al. Real-world experience treating pediatric epilepsy patients with cenobamate. Front Neurol. 2022;13: 950171.","journal-title":"Front Neurol"},{"key":"1063_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108679","volume":"130","author":"RT Varughese","year":"2022","unstructured":"Varughese RT, Shah YD, Karkare S, et al. Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: a single-center retrospective study. Epilepsy Behav. 2022;130: 108679.","journal-title":"Epilepsy Behav"},{"key":"1063_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pediatrneurol.2022.01.001","volume":"129","author":"T Elliott","year":"2022","unstructured":"Elliott T, Ridley-Pryor T, Gienapp AJ, et al. Initial real-world experience with cenobamate in adolescents and adults: a single center experience. Pediatr Neurol. 2022;129:19\u201323.","journal-title":"Pediatr Neurol"},{"key":"1063_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12857","author":"J Catal\u00e1n-Aguilar","year":"2023","unstructured":"Catal\u00e1n-Aguilar J, Hampel KG, Cano-L\u00f3pez I, et al. Prospective study of cenobamate on cognition, affectivity, and quality of life in focal epilepsy. Epilepsia Open. 2023. https:\/\/doi.org\/10.1002\/epi4.12857. (Epub ahead of print).","journal-title":"Epilepsia Open"},{"key":"1063_CR34","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.euroneuro.2015.07.027","volume":"25","author":"J-A Witt","year":"2015","unstructured":"Witt J-A, Elger CE, Helmstaedter C. Adverse cognitive effects of antiepileptic pharmacotherapy: each additional drug matters. Eur Neuropsychopharmacol. 2015;25:1954\u20139.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1063_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12757","author":"V Villanueva","year":"2023","unstructured":"Villanueva V, Santos-Carrasco D, Cabezudo-Garc\u00eda P, et al. Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an expanded access program. Epilepsia Open. 2023. https:\/\/doi.org\/10.1002\/epi4.12757. (Online ahead of print).","journal-title":"Epilepsia Open"},{"issue":"12","key":"1063_CR36","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1111\/epi.17091","volume":"62","author":"MR Sperling","year":"2021","unstructured":"Sperling MR, Abou-Khalil B, Aboumatar S, et al. Efficacy of cenobamate for uncontrolled focal seizures: post hoc analysis of a phase 3, multicenter, open-label study. Epilepsia. 2021;62(12):3005\u201315.","journal-title":"Epilepsia"},{"key":"1063_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106592","volume":"172","author":"WE Rosenfeld","year":"2021","unstructured":"Rosenfeld WE, Nisman A, Ferrari L. Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: a post-hoc analysis of a randomized clinical study. Epilepsy Res. 2021;172: 106592.","journal-title":"Epilepsy Res"},{"key":"1063_CR38","doi-asserted-by":"publisher","DOI":"10.2174\/1871527321666220113110044","author":"MA Barbieri","year":"2022","unstructured":"Barbieri MA, Perucca E, Spina E, et al. Cenobamate: a review of its pharmacological properties, clinical efficacy and tolerability profile in the treatment of epilepsy. CNS Neurol Disord Drug Targets. 2022. https:\/\/doi.org\/10.2174\/1871527321666220113110044. (Epub ahead of print).","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"1063_CR39","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.yebeh.2012.09.015","volume":"26","author":"J-A Witt","year":"2013","unstructured":"Witt J-A, Helmstaedter C. Monitoring the cognitive effects of antiepileptic pharmacotherapy\u2014approaching the individual patient. Epilepsy Behav. 2013;26:450\u20136.","journal-title":"Epilepsy Behav"},{"key":"1063_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3988\/jcn.2008.4.3.99","volume":"4","author":"S-P Park","year":"2008","unstructured":"Park S-P, Kwon S-H. Cognitive effects of antiepileptic drugs. J Clin Neurol. 2008;4:99\u2013106.","journal-title":"J Clin Neurol"},{"key":"1063_CR41","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/epi.13279","volume":"57","author":"KJ Meador","year":"2016","unstructured":"Meador KJ, Yang H, Pina-Garza JE, et al. Cognitive effects of adjunctive perampanel for partial-onset seizures: a randomized trial. Epilepsia. 2016;57:243\u20135.","journal-title":"Epilepsia"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01063-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01063-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01063-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T15:32:15Z","timestamp":1708529535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01063-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1063"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01063-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"assertion":[{"value":"8 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for open access publishing: Universidad M\u00e1laga\/CBUA. This study has been funded by Andalusian Network of Clinical and Translational Research in Neurology (Neuro-RECA) of the Ministry of Health and Consumer Affairs of Andalusia (code: RIC-0111-2019). Open access for this paper has been sponsored by the University of Malaga.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"PJSC has received consultant and\/or speaker honoraria from Angelini Pharma, Bial, Eisai, GW Pharmaceuticals (now a part of Jazz Pharmaceuticals), Roche Pharmaceuticals, UCB Pharma, and Zogenix Espa\u00f1a. PCG has received consultant and\/or speaker honoraria from Angelini-Pharma, Bial, Eisai, GW Pharmaceuticals (now a part of Jazz Pharmaceuticals), UCB Pharma, Exeltis, and Neuraxpharm. GGM has received consultant and\/or speaker honoraria from Bial, Eisai, GW Pharmaceuticals (now a part of Jazz Pharmaceuticals), and UCB Pharma. JDP belongs to the Medical Department of Angelini pharmaceuticals. TRG has no disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"We confirm that we have read the journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. The study protocol was approved by the hospital\u2019s ethics committee and was in accordance with the code of ethics set out in the 1964 Declaration of Helsinki and its later amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"For all patients participating in the Spanish cenobamate EAP, written informed consent was obtained from the patient or their legal representative.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Anonymized data not published within this article will be made available by request from any qualified investigator.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"PJSC*: Major role in the acquisition of data, study concept or design, and analysis or interpretation of data. TRG*: Major role in the acquisition of data, study concept or design, and analysis or interpretation of data. PCG: Analysis or interpretation of data. GGM: Analysis or interpretation of data. JDP: Study concept or design. *PJSC and TRG contributed equally to this paper. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s Contributions"}}]}}